Charles River(CRL) - 2023 Q1 - Earnings Call Presentation

▪ Believe early-stage research we conduct is instrumental to our biotech clients' achievement of important milestones that enable them to secure additional funding Concluding Remarks, cont. ─ Investing in technology partnerships to bring cutting-edge tools to our clients EVERY STEP OF THE WAY ─ Delivered strong organic revenue growth, widely outperforming prior expectations ▪ Narrowed 2023 financial guidance to reflect strong 1Q23 performance ─ Anticipated gating of NHP supply impact, which will principally ...